# Evaluation of a Pharmacogenetic-based Warfarin Dosing Algorithm in Patients

Study · id `cardio:ct-nct02592980` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02592980](<https://clinicaltrials.gov/study/NCT02592980>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02592980

Browse, organ or system: Heart  
Browse, condition area: Stroke; Heart rhythm problems  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 300 participants.

## Technical summary

Registry record NCT02592980. Randomized; single masking; primary purpose treatment. Start 2016-01 (actual); primary completion 2019-11 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 300 participants (planned count; ClinicalTrials.gov record NCT02592980, source copy `cardio:ctgov-nct02592980-2019-07-05`, retrieved 2026-10-26)
- Started: 2016-01 (actual) (ClinicalTrials.gov record NCT02592980, source copy `cardio:ctgov-nct02592980-2019-07-05`, retrieved 2026-10-26)
- Primary completion: 2019-11 (anticipated) (ClinicalTrials.gov record NCT02592980, source copy `cardio:ctgov-nct02592980-2019-07-05`, retrieved 2026-10-26)
- Completion: 2020-12 (anticipated) (ClinicalTrials.gov record NCT02592980, source copy `cardio:ctgov-nct02592980-2019-07-05`, retrieved 2026-10-26)
- Countries: Brazil (ClinicalTrials.gov record NCT02592980, source copy `cardio:ctgov-nct02592980-2019-07-05`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02592980-2019-07-05`, retrieved 2026-10-26)

## The registry's words

- Brief title: Evaluation of a Pharmacogenetic-based Warfarin Dosing Algorithm in Patients
- Condition: Atrial Fibrillation
- Intervention (Genetic): Pharmacogenetic anticoagulation
- Intervention (Drug): Traditional anticoagulation
- Lead sponsor: University of Sao Paulo General Hospital
- Lead sponsor class: OTHER
- Collaborator: InCor Heart Institute
- Collaborator class: OTHER
- Collaborator: Farmoquimica S.A.
- Collaborator class: INDUSTRY
- Collaborator: University of Sao Paulo
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)
- Registry lists this organization as the lead sponsor: University of Sao Paulo General Hospital (`cardio:org-university-of-sao-paulo-general-hospital`)
- Registry lists this organization as a collaborator: InCor Heart Institute (`cardio:org-incor-heart-institute`)
- Registry lists this organization as a collaborator: University of Sao Paulo (`cardio:org-university-of-sao-paulo`)

## Provenance

Content hash: 884bcfbcb0ed885468a177e68808df02b1986b4f8621247937fd62f15702a311
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
